Copyright Reports & Markets. All rights reserved.

Global Gene Therapy in CNS Disorder Market 2026 by Company, Regions, Type and Application, Forecast to 2032

Request for Sample of this report
Buy now

1 Market Overview

  • 1.1 Product Overview and Scope
  • 1.2 Market Estimation Caveats and Base Year
  • 1.3 Classification of Gene Therapy in CNS Disorder by Type
    • 1.3.1 Overview: Global Gene Therapy in CNS Disorder Market Size by Type: 2021 Versus 2025 Versus 2032
    • 1.3.2 Global Gene Therapy in CNS Disorder Consumption Value Market Share by Type in 2025
    • 1.3.3 Viral Gene Therapy
    • 1.3.4 Non-viral Gene Therapy
  • 1.4 Global Gene Therapy in CNS Disorder Market by Application
    • 1.4.1 Overview: Global Gene Therapy in CNS Disorder Market Size by Application: 2021 Versus 2025 Versus 2032
    • 1.4.2 Alzheimer's Disease
    • 1.4.3 Huntington's Disease
    • 1.4.4 Parkinson's Disease
    • 1.4.5 Batten Disease
  • 1.5 Global Gene Therapy in CNS Disorder Market Size & Forecast
  • 1.6 Global Gene Therapy in CNS Disorder Market Size and Forecast by Region
    • 1.6.1 Global Gene Therapy in CNS Disorder Market Size by Region: 2021 VS 2025 VS 2032
    • 1.6.2 Global Gene Therapy in CNS Disorder Market Size by Region, (2021-2032)
    • 1.6.3 North America Gene Therapy in CNS Disorder Market Size and Prospect (2021-2032)
    • 1.6.4 Europe Gene Therapy in CNS Disorder Market Size and Prospect (2021-2032)
    • 1.6.5 Asia-Pacific Gene Therapy in CNS Disorder Market Size and Prospect (2021-2032)
    • 1.6.6 South America Gene Therapy in CNS Disorder Market Size and Prospect (2021-2032)
    • 1.6.7 Middle East & Africa Gene Therapy in CNS Disorder Market Size and Prospect (2021-2032)

2 Company Profiles

  • 2.1 Voyager Therapeutics
    • 2.1.1 Voyager Therapeutics Details
    • 2.1.2 Voyager Therapeutics Major Business
    • 2.1.3 Voyager Therapeutics Gene Therapy in CNS Disorder Product and Solutions
    • 2.1.4 Voyager Therapeutics Gene Therapy in CNS Disorder Revenue, Gross Margin and Market Share (2021-2026)
    • 2.1.5 Voyager Therapeutics Recent Developments and Future Plans
  • 2.2 Spark Therapeutics
    • 2.2.1 Spark Therapeutics Details
    • 2.2.2 Spark Therapeutics Major Business
    • 2.2.3 Spark Therapeutics Gene Therapy in CNS Disorder Product and Solutions
    • 2.2.4 Spark Therapeutics Gene Therapy in CNS Disorder Revenue, Gross Margin and Market Share (2021-2026)
    • 2.2.5 Spark Therapeutics Recent Developments and Future Plans
  • 2.3 Novartis AG
    • 2.3.1 Novartis AG Details
    • 2.3.2 Novartis AG Major Business
    • 2.3.3 Novartis AG Gene Therapy in CNS Disorder Product and Solutions
    • 2.3.4 Novartis AG Gene Therapy in CNS Disorder Revenue, Gross Margin and Market Share (2021-2026)
    • 2.3.5 Novartis AG Recent Developments and Future Plans
  • 2.4 Bluebird Bio Inc.
    • 2.4.1 Bluebird Bio Inc. Details
    • 2.4.2 Bluebird Bio Inc. Major Business
    • 2.4.3 Bluebird Bio Inc. Gene Therapy in CNS Disorder Product and Solutions
    • 2.4.4 Bluebird Bio Inc. Gene Therapy in CNS Disorder Revenue, Gross Margin and Market Share (2021-2026)
    • 2.4.5 Bluebird Bio Inc. Recent Developments and Future Plans
  • 2.5 Biogen
    • 2.5.1 Biogen Details
    • 2.5.2 Biogen Major Business
    • 2.5.3 Biogen Gene Therapy in CNS Disorder Product and Solutions
    • 2.5.4 Biogen Gene Therapy in CNS Disorder Revenue, Gross Margin and Market Share (2021-2026)
    • 2.5.5 Biogen Recent Developments and Future Plans

3 Market Competition, by Players

  • 3.1 Global Gene Therapy in CNS Disorder Revenue and Share by Players (2021-2026)
  • 3.2 Market Share Analysis (2025)
    • 3.2.1 Market Share of Gene Therapy in CNS Disorder by Company Revenue
    • 3.2.2 Top 3 Gene Therapy in CNS Disorder Players Market Share in 2025
    • 3.2.3 Top 6 Gene Therapy in CNS Disorder Players Market Share in 2025
  • 3.3 Gene Therapy in CNS Disorder Market: Overall Company Footprint Analysis
    • 3.3.1 Gene Therapy in CNS Disorder Market: Region Footprint
    • 3.3.2 Gene Therapy in CNS Disorder Market: Company Product Type Footprint
    • 3.3.3 Gene Therapy in CNS Disorder Market: Company Product Application Footprint
  • 3.4 New Market Entrants and Barriers to Market Entry
  • 3.5 Mergers, Acquisition, Agreements, and Collaborations

4 Market Size Segment by Type

  • 4.1 Global Gene Therapy in CNS Disorder Consumption Value and Market Share by Type (2021-2026)
  • 4.2 Global Gene Therapy in CNS Disorder Market Forecast by Type (2027-2032)

5 Market Size Segment by Application

  • 5.1 Global Gene Therapy in CNS Disorder Consumption Value Market Share by Application (2021-2026)
  • 5.2 Global Gene Therapy in CNS Disorder Market Forecast by Application (2027-2032)

6 North America

  • 6.1 North America Gene Therapy in CNS Disorder Consumption Value by Type (2021-2032)
  • 6.2 North America Gene Therapy in CNS Disorder Market Size by Application (2021-2032)
  • 6.3 North America Gene Therapy in CNS Disorder Market Size by Country
    • 6.3.1 North America Gene Therapy in CNS Disorder Consumption Value by Country (2021-2032)
    • 6.3.2 United States Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 6.3.3 Canada Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 6.3.4 Mexico Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)

7 Europe

  • 7.1 Europe Gene Therapy in CNS Disorder Consumption Value by Type (2021-2032)
  • 7.2 Europe Gene Therapy in CNS Disorder Consumption Value by Application (2021-2032)
  • 7.3 Europe Gene Therapy in CNS Disorder Market Size by Country
    • 7.3.1 Europe Gene Therapy in CNS Disorder Consumption Value by Country (2021-2032)
    • 7.3.2 Germany Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 7.3.3 France Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 7.3.4 United Kingdom Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 7.3.5 Russia Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 7.3.6 Italy Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)

8 Asia-Pacific

  • 8.1 Asia-Pacific Gene Therapy in CNS Disorder Consumption Value by Type (2021-2032)
  • 8.2 Asia-Pacific Gene Therapy in CNS Disorder Consumption Value by Application (2021-2032)
  • 8.3 Asia-Pacific Gene Therapy in CNS Disorder Market Size by Region
    • 8.3.1 Asia-Pacific Gene Therapy in CNS Disorder Consumption Value by Region (2021-2032)
    • 8.3.2 China Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 8.3.3 Japan Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 8.3.4 South Korea Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 8.3.5 India Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 8.3.6 Southeast Asia Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 8.3.7 Australia Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)

9 South America

  • 9.1 South America Gene Therapy in CNS Disorder Consumption Value by Type (2021-2032)
  • 9.2 South America Gene Therapy in CNS Disorder Consumption Value by Application (2021-2032)
  • 9.3 South America Gene Therapy in CNS Disorder Market Size by Country
    • 9.3.1 South America Gene Therapy in CNS Disorder Consumption Value by Country (2021-2032)
    • 9.3.2 Brazil Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 9.3.3 Argentina Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)

10 Middle East & Africa

  • 10.1 Middle East & Africa Gene Therapy in CNS Disorder Consumption Value by Type (2021-2032)
  • 10.2 Middle East & Africa Gene Therapy in CNS Disorder Consumption Value by Application (2021-2032)
  • 10.3 Middle East & Africa Gene Therapy in CNS Disorder Market Size by Country
    • 10.3.1 Middle East & Africa Gene Therapy in CNS Disorder Consumption Value by Country (2021-2032)
    • 10.3.2 Turkey Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 10.3.3 Saudi Arabia Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)
    • 10.3.4 UAE Gene Therapy in CNS Disorder Market Size and Forecast (2021-2032)

11 Market Dynamics

  • 11.1 Gene Therapy in CNS Disorder Market Drivers
  • 11.2 Gene Therapy in CNS Disorder Market Restraints
  • 11.3 Gene Therapy in CNS Disorder Trends Analysis
  • 11.4 Porters Five Forces Analysis
    • 11.4.1 Threat of New Entrants
    • 11.4.2 Bargaining Power of Suppliers
    • 11.4.3 Bargaining Power of Buyers
    • 11.4.4 Threat of Substitutes
    • 11.4.5 Competitive Rivalry

12 Industry Chain Analysis

  • 12.1 Gene Therapy in CNS Disorder Industry Chain
  • 12.2 Gene Therapy in CNS Disorder Upstream Analysis
  • 12.3 Gene Therapy in CNS Disorder Midstream Analysis
  • 12.4 Gene Therapy in CNS Disorder Downstream Analysis

13 Research Findings and Conclusion

    14 Appendix

    • 14.1 Methodology
    • 14.2 Research Process and Data Source

    According to our (Global Info Research) latest study, the global Gene Therapy in CNS Disorder market size was valued at US$ 787 million in 2025 and is forecast to a readjusted size of US$ 2065 million by 2032 with a CAGR of 14.9% during review period.
    Gene therapy entails the specific transfer of genetic information into affected cells and tissues in order to restore function in diseased areas.
    The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
    This report is a detailed and comprehensive analysis for global Gene Therapy in CNS Disorder market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2025, are provided.
    Key Features:
    Global Gene Therapy in CNS Disorder market size and forecasts, in consumption value ($ Million), 2021-2032
    Global Gene Therapy in CNS Disorder market size and forecasts by region and country, in consumption value ($ Million), 2021-2032
    Global Gene Therapy in CNS Disorder market size and forecasts, by Type and by Application, in consumption value ($ Million), 2021-2032
    Global Gene Therapy in CNS Disorder market shares of main players, in revenue ($ Million), 2021-2026
    The Primary Objectives in This Report Are:
    To determine the size of the total market opportunity of global and key countries
    To assess the growth potential for Gene Therapy in CNS Disorder
    To forecast future growth in each product and end-use market
    To assess competitive factors affecting the marketplace
    This report profiles key players in the global Gene Therapy in CNS Disorder market based on the following parameters - company overview, revenue, gross margin, product portfolio, geographical presence, and key developments. Key companies covered as a part of this study include Voyager Therapeutics, Spark Therapeutics, Novartis AG, Bluebird Bio Inc., Biogen, etc.
    This report also provides key insights about market drivers, restraints, opportunities, new product launches or approvals.
    Market segmentation
    Gene Therapy in CNS Disorder market is split by Type and by Application. For the period 2021-2032, the growth among segments provides accurate calculations and forecasts for Consumption Value by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
    Market segment by Type
    Viral Gene Therapy
    Non-viral Gene Therapy
    Market segment by Application
    Alzheimer's Disease
    Huntington's Disease
    Parkinson's Disease
    Batten Disease
    Market segment by players, this report covers
    Voyager Therapeutics
    Spark Therapeutics
    Novartis AG
    Bluebird Bio Inc.
    Biogen
    Market segment by regions, regional analysis covers
    North America (United States, Canada and Mexico)
    Europe (Germany, France, UK, Russia, Italy and Rest of Europe)
    Asia-Pacific (China, Japan, South Korea, India, Southeast Asia and Rest of Asia-Pacific)
    South America (Brazil, Rest of South America)
    Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
    The content of the study subjects, includes a total of 13 chapters:
    Chapter 1, to describe Gene Therapy in CNS Disorder product scope, market overview, market estimation caveats and base year.
    Chapter 2, to profile the top players of Gene Therapy in CNS Disorder, with revenue, gross margin, and global market share of Gene Therapy in CNS Disorder from 2021 to 2026.
    Chapter 3, the Gene Therapy in CNS Disorder competitive situation, revenue, and global market share of top players are analyzed emphatically by landscape contrast.
    Chapter 4 and 5, to segment the market size by Type and by Application, with consumption value and growth rate by Type, by Application, from 2021 to 2032.
    Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2021 to 2026.and Gene Therapy in CNS Disorder market forecast, by regions, by Type and by Application, with consumption value, from 2027 to 2032.
    Chapter 11, market dynamics, drivers, restraints, trends, Porters Five Forces analysis.
    Chapter 12, the key raw materials and key suppliers, and industry chain of Gene Therapy in CNS Disorder.
    Chapter 13, to describe Gene Therapy in CNS Disorder research findings and conclusion.

    Buy now